Kintor Pharmaceutical Limited Reports Major Progress in KT-939 Development
Key Highlights for Investors
- Positive interim safety trial results: No adverse skin reactions observed in long-term human trial.
- Commencement of registration application: KT-939 submitted as a new cosmetic raw material to China’s regulatory authorities.
- Business partnership progress: Strategic collaborations with domestic and international cosmetics brands underway.
- Accelerated global patent protection: KT-939 and its analogs entering priority review in key regions.
Detailed Report
1. Positive Interim Result in Long-Term Human Safety Trial of KT-939
Kintor Pharmaceutical Limited has released an update on its flagship product, KT-939, reporting positive interim results from a long-term human safety trial. The study is an open-label, single-arm, single-center trial designed to assess the safety of long-term topical application of cosmetics containing 0.2% KT-939 over 52 consecutive weeks.
As of the interim analysis, 119 subjects received continuous KT-939 application for 28 weeks. Importantly, none of the participants experienced any adverse skin reactions—including cosmetic contact dermatitis, photosensitivity dermatitis, hyperpigmentation, contact urticaria, or cosmetic acne. This demonstrates a robust safety profile for KT-939, which is a critical milestone for product regulatory approval and commercialization. The trial is expected to conclude in September 2026.
2. Launch of Registration Application for New Cosmetic Raw Material KT-939
In accordance with China’s Regulations on Supervision and Administration of Cosmetics, new raw materials used in high-risk cosmetic products (freckle-removing, whitening, etc.) must be registered and approved by the National Medical Products Administration (NMPA) before market launch. Kintor has officially commenced the rolling submission of registration materials for KT-939, including safety, efficacy, manufacturing, and quality control documentation.
The technical documents have been submitted to the National Institutes for Food and Drug Control (NIFDC), an affiliate of the NMPA, to facilitate technical communication and exchanges. Kintor will follow NIFDC guidance to advance the application process, which is crucial for commercialization and could strongly influence the company’s market position and share price.
3. Business Partnership Progress on KT-939
Despite competitive challenges, Kintor continues to pursue an open and collaborative approach, targeting global consumers with high-quality, innovative whitening cosmetics. The company is actively advancing partnerships with international and domestic cosmetics brands, raw material suppliers, and end-product developers. China’s regulations require a special cosmetics registration certificate for whitening products, and encourage simultaneous registration of special cosmetic products and innovative raw materials.
Kintor expects to form strategic partnerships with more domestic and international brands in the whitening category, which could accelerate product development and broaden market reach. This partnership expansion may significantly impact future revenues and share value.
4. Patent Application Progress of KT-939 Series Innovative Compounds
Kintor has a strong track record in small molecule innovation, leveraging AI technology in chemical design. The company has filed and obtained over 100 national patents, establishing a robust technical protection mechanism.
The patent process for KT-939 and its analogs is being accelerated globally, with the project entering examination in relevant countries and priority review requested in key regions. This global intellectual property network will provide legal protection for KT-939’s clinical development and commercialization, reducing risk and potentially enhancing shareholder value.
What Shareholders Need to Know
- The positive safety trial results for KT-939 are a major milestone and significantly de-risk the product’s path to market.
- The launch of registration application in China is a critical step toward regulatory approval and commercialization, which could drive future sales growth and share price appreciation.
- Active pursuit of global partnerships and patent protection enhances KT-939’s commercial viability and competitive positioning.
- Any delays or negative feedback in regulatory or partnership processes may impact share value, but the current progress signals strong momentum.
Conclusion: All developments reported are potentially price-sensitive and could move Kintor Pharmaceutical’s share price. Investors should closely monitor the completion of the safety trial, regulatory registration progress, partnership announcements, and patent milestones.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with professional advisors before making investment decisions. The information is based on company announcements and may be subject to change.
Kintor藥業有限公司公布KT-939發展重大進展
投資者重點
- 安全測試中期結果正面：長期人體測試未見任何皮膚不良反應。
- 啟動註冊申請：KT-939作為新化妝品原料已向中國監管部門遞交申請。
- 業務合作進展：正與國內外化妝品牌合作推進戰略協作。
- 加速全球專利保護：KT-939及其類似系列已進入關鍵地區優先審查。
詳細報導
1. KT-939長期人體安全測試正面中期結果
Kintor藥業公布其主打產品KT-939的長期人體安全測試取得正面中期結果。此開放式、單臂、單中心研究旨在評估含0.2% KT-939化妝品長期使用（連續52週）對皮膚安全性。
中期分析顯示，119名受試者連續28週使用KT-939，全部未見任何皮膚不良反應，包括化妝品接觸性皮炎、光敏性皮炎、色素過度、蕁麻疹及化妝品痤瘡。KT-939的安全性已充分展現，對產品上市及監管審批至關重要。該測試預計於2026年9月完成。
2. 新原料KT-939註冊申請啟動
按中國《化妝品監督管理條例》，高風險化妝品（如祛斑、美白等）新原料需經國家藥品監督管理局（NMPA）註冊審批方可上市。Kintor已啟動KT-939註冊材料滾動提交，包括安全、效能、製程及質控文件。
技術文件已提交至國家食品藥品監督管理局下屬機構（NIFDC），進行技術交流。公司將跟進NIFDC指導，推進KT-939註冊進程，這對商業化及股價有重大影響。
3. KT-939業務合作進展
面對競爭挑戰，Kintor仍積極推動開放協作，主攻全球高品質美白化妝品市場。公司正與國內外化妝品牌、原料供應商及終端產品開發商全面推進合作。中國規定美白產品需取得特種化妝品註冊證書，並鼓勵新原料及產品同步申請。
Kintor預期將與更多國內外品牌建立戰略合作，加快產品開發與市場布局，對未來收入及股價有正面影響。
4. KT-939系列創新化合物專利申請進展
Kintor在小分子創新領域有豐富經驗，並運用人工智能技術，已申請並獲得超過100項國家專利，建立了強大的技術保護機制。
KT-939及其類似物全球專利進程加速，已進入相關國家審查並在關鍵地區申請優先審查。全球知識產權網絡將為KT-939臨床發展及商業化提供法律保障，減低風險並有機會提升股東價值。
股東須知
- KT-939安全測試正面結果大大降低產品上市風險。
- 中國註冊申請啟動是產品上市前的重要一步，料可推動未來銷售增長及股價上升。
- 積極推進全球合作及專利保護，有利KT-939商業化及競爭力。
- 監管或合作進程若有延誤或負面消息或影響股價，目前進展顯示公司勢頭強勁。
總結：上述進展均屬價值敏感消息，有機會推動Kintor藥業股價。投資者應密切留意安全測試完成、註冊進度、合作及專利里程碑。
免責聲明
本文章僅供資訊參考，並不構成投資建議。投資者應自行研究或咨詢專業顧問後決定。內容根據公司公告編寫，或有變動。
